IPA: Inhibition of platelet aggregation ... The combined use of antiplatelet drugs acting through different mechanisms is important in antithrombotic treatment of patients with cardiovascular ...

During a Case-Based Roundtable® event, Nakhle Saba, MD, and participants discussed the data supporting the 2 newer BTK ...

The first patient has been enrolled in a Phase 1 trial by the NHLBI that's evaluating fostamatinib as a treatment for sickle ...

Scientists in Melbourne have given cancer patients a ray of hope after they found that a new combination drug therapy would revolutionize the treatment for the deadly disease. A new combination ...

After more than 70 years of effective clinical use, heparin remains the most common anticoagulant in use and one of the most commonly prescribed drugs to ... Direct inhibition of thrombin may ...

The antibody-drug conjugate improved progression-free survival for patients previously treated with hormone therapy.

Head of Investor Relations Welcome to the Q4 and full year 2024 conference call for investors and analysts. As usual, you can find the slides on sanofi.com. Please turn to Slide 3. Here we have the ...

Enhertu is a HER2-directed antibody and topoisomerase inhibitor conjugate. Approval of the new indication was based on data from the phase 3 DESTINY-Breast06 trial (ClinicalTrials.gov Identifier: ...

Impact and progress Frontiers' impact Progress Report 2022 All progress reports ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...

Sanofi (NASDAQ:SNY) reported robust financial results for the fourth quarter of 2024, driven by significant sales growth and a solid increase in earnings per share (EPS). The company's net sales rose ...